Follicle-stimulating hormone (FSH) receptor gene polymorphisms in Iraqi patients with non-obstructive azoospermia
| Autor: | Ula M. Al-Kawaz, Omar Abdul-Rasheed, Abdul-Rahim A. Ali |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Non obstructive azoospermia
medicine.medical_specialty endocrine system Computer Networks and Communications QH301-705.5 follicle-stimulating hormone receptor rs6166 rs6165 QD415-436 Microbiology Biochemistry male infertility Diseases of the endocrine glands. Clinical endocrinology Follicle-stimulating hormone single nucleotide polymorphism Internal medicine medicine non-obstructive azoospermia Biology (General) business.industry RC648-665 QR1-502 Endocrinology Hardware and Architecture Fsh receptor gene business Software TP248.13-248.65 Biotechnology |
| Zdroj: | Baghdad Journal of Biochemistry and Applied Biological Sciences, Vol 2, Iss 04, Pp 187-202 (2021) |
| ISSN: | 2706-9915 |
| Popis: | Background: Follicle-stimulating hormone (FSH) is a pivotal hormone for male fertility, and its action on gonads is exerted by FSH receptors (FSHRs). Objectives: To examine whether the presence of FSHR gene single nucleotide polymorphisms (SNPs), G919A and A2039G, involved in non-obstructive azoospermia (NOA) in Iraqi infertile men. Methods: Two common SNPs, A919G and A2039G, in the FSHR gene were analyzed in 104 subjects (70 infertile patients with NOO: 33 NOA patients were not receiving treatment and 37 were on infertility treatment, and 34 normozoospermic fertile men as controls). Results: The results revealed that the homozygous wild genotype (AA) of rs6165 FSHR gene SNP was more abundant than (AG) and (GG) genotypes in both groups of infertile NOA patients with a frequency of 49% in those who untreated, 81% in patients undergoing treatment and in the control group 41%. Whereas, the highest percentage of heterozygous genotype (AG) in the fertile control group was 41% when compared to NOApatients with a genotype frequency of 24% (for those who untreated) and 11% (for patients on treatment), respectively; with (A) allele frequency of 86% and the observed frequency of (G) allele was only 14% in the patients’ group as compared to that of controls that were (65 %) and (35 %), respectively. The rs6166 genotyping revealed that the homozygous wild genotype (GG) of FSHR gene was more abundant than (AG) and (AA) genotypes in NOA patients receiving infertility treatment with a frequency of (68%), in NOA patients who didn’t receive treatment 49%, while the lowest frequency was detected in the healthy fertile control group (47%). Conclusions: These results support the evidence that rs6165 and rs6166, FSHR SNPs, might be involved in the pathogenesis and protection against NOA, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|